Top Tweets for #immds

These following points collectively underline the regulatory failures and the need for systemic changes within the MHRA to better protect patient safety and ensure more effective regulatory practices. The report's findings have sparked debates and calls for action to reform how regulatory bodies, especially the MHRA, handle patient safety and product oversight in the UK 🔷Lack of Coordination and Accountability: The report criticized the healthcare system, including the MHRA, for being disjointed, siloed, unresponsive, and defensive. There was noted to be a lack of effective linkage between various regulatory bodies, leading to a fragmented approach to patient safety and regulatory oversight. 🔷Adverse Event Reporting: The MHRA's system for adverse event reporting, known as the Yellow Card scheme, was highlighted as 🔹needing substantial revision🔹. There was a noted lack of awareness among both the public and healthcare professionals, which hampers the ability to detect significant adverse outcomes promptly. 🔷Regulation of Medical Devices: The report pointed out that the MHRA did not engage in the pre-market phase of medical device development, suggesting a need for a more proactive regulatory role, particularly in relation to adverse event reporting and medical device regulation. It was suggested that the regulatory framework for medical devices should be at least as stringent as the EU Medical Devices Regulations. 🔷Patient Engagement: There was a call for improved engagement with patients by the MHRA to ensure that patients have an integral role in regulatory processes, including safety assessments and decision-making. 🔷Transparency and Learning from Mistakes: The report emphasized the need for greater transparency in adverse event reporting and a cultural shift from denial to learning from mistakes to enhance patient safety. 🔷Post-Marketing Surveillance: The review highlighted the necessity for more robust post-marketing surveillance of both medicines and medical devices to monitor long-term safety and efficacy, which was seen as lacking under the current MHRA practices. #MHRA #regulatoryreform #medicines #medicaldevices #healthcare #yellowcard #Reform #patientsafety